Miriyala Preethika
Research Subjects
Research Interests
Miriyala Preethika has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Afsar Shaik
Faculty of Health Sciences, Villa College – QI Campus, RahDhebai Hingun, Boduthakurufaanu Magu Male – 20373, Maldives
1 shared publication - Kollipara Naga Venkata Chenchu Lakshmi
Department of Pharmacy KL College of Pharmacy Koneru Lakshmaiah Education Foundation (KLEF) Vaddeswaram Andhra Pradesh India
1 shared publication - Krishnaveni Manubolu
Narayana Pharmacy College, India
1 shared publication - Nimmagadda Sai Sruthi1 shared publication
- Raveesha Peeriga
V.V. Institute of Pharmaceutical Sciences, India
1 shared publication - Talamanchi Balakrishna
V.V. Institute of Pharmaceutical Sciences
1 shared publication
Latest Publications
- 10 July 2025
- Published by Taylor & Francis
- p. 264-296
Conclusion and Future Prospects on Drug Discovery
In this chapter, we summarize recent progress in drug discovery and assess its implications for future research and development. The final section summarizes recent key findings from high-throughput screening (HTS), biomarker identification and personalized medicine. Moreover, it identifies the challenges encountered, like high costs, extended development cycles and both regulatory and commercial hurdles. Emerging trends in drug discovery, such as artificial intelligence (AI), genomic integration, and new therapeutic modalities, are explored as future prospects. By highlighting the successes, the challenges that persist, and the innovations that might alter the face of drug development, this analysis covers the full version of the progress to date. Results highlight a need for sustained interdisciplinary partnerships and continued investment in state-of-the-art technologies to overcome current constraints and progress discovery toward new, effective therapies.
- 10 July 2025
- Published by Taylor & Francis
- p. 264-296
Conclusion and Future Prospects on Drug Discovery
In this chapter, we summarize recent progress in drug discovery and assess its implications for future research and development. The final section summarizes recent key findings from high-throughput screening (HTS), biomarker identification and personalized medicine. Moreover, it identifies the challenges encountered, like high costs, extended development cycles and both regulatory and commercial hurdles. Emerging trends in drug discovery, such as artificial intelligence (AI), genomic integration, and new therapeutic modalities, are explored as future prospects. By highlighting the successes, the challenges that persist, and the innovations that might alter the face of drug development, this analysis covers the full version of the progress to date. Results highlight a need for sustained interdisciplinary partnerships and continued investment in state-of-the-art technologies to overcome current constraints and progress discovery toward new, effective therapies.